ライフサイエンスコーパス: antihypertensive

1 midodrine, 50% were concomitantly prescribed antihypertensives.

2 all survival compared with patients on other antihypertensives.

3 p were able to achieve SPRINT levels without antihypertensives.

4 etics are among the most commonly prescribed antihypertensives.

5 es in prescription rates of both statins and antihypertensives.

6 nexpander states saw declines in statins and antihypertensives.

7 7% in statins (11.0 to 20.8 million), 76% in antihypertensives (35.3 to 62.2 million), and 37% in P2Y

8 tia (1 trial, low strength of evidence); and antihypertensives (4 trials), NSAIDs (1 trial), and stat

9 ding 3 that studied dementia medications, 16 antihypertensives, 4 diabetes medications, 2 nonsteroida

10 eat fermented by L. plantarum had pronounced antihypertensive activities (~85%).

11 Pig meat showed antioxidative and antihypertensive activities, heat treatment decreased th

12 nship between structure and dual antioxidant/antihypertensive activity of lentil peptides opening new

13 y matured nanobody antagonist has comparable antihypertensive activity to the angiotensin receptor bl

14 exhibits immunomodulatory, antimicrobial and antihypertensive activity.

15 9), as well as alphas2-casein (189-197) have antihypertensive activity.

16 rom fermented milk, has been associated with antihypertensive activity.

17 Treatment with an antihypertensive agent alone is often insufficient to co

18 mg dose remains the most commonly prescribed antihypertensive agent in the United States.

19 Blood pressure lowering with antihypertensive agents compared with control was signif

20 linical trials, blood pressure lowering with antihypertensive agents compared with control was signif

21 controlled blood pressure despite use of >=5 antihypertensive agents of different classes, including

22 rolled blood pressure despite the use of >=3 antihypertensive agents of different classes, including

23 od pressure threshold for treatment, and the antihypertensive agents to be used.

24 All major classes of antihypertensive agents were included.

25 ssure control, a sodium-restricted diet, and antihypertensive agents).

26 farin (presumably for deep-vein thrombosis), antihypertensive agents, and a statin.

27 e >/=160 mm Hg despite taking at least three antihypertensive agents, including a diuretic).

28 unction score, need for vasopressors, use of antihypertensive agents, need for mechanical ventilation

29 ups consisted of either placebo, alternative antihypertensive agents, or higher blood pressure target

30 promising natural source of antioxidants and antihypertensive agents.

31 apy, thrombocyte aggregation inhibitors, and antihypertensive and antidiabetic medication.

32 dings revealed that WMRP displayed excellent antihypertensive and antioxidant activities.

33 hnicity, smoking, height, weight, and use of antihypertensive and lipid-lowering drugs.

34 erformed a secondary analysis of the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent

35 of the model was performed in data from the Antihypertensive and Lipid-Lowering Treatment to Prevent

36 Expected absolute risk reductions for antihypertensive and lipid-lowering treatment were asses

37 than among controls, as was the use of other antihypertensive and non-antihypertensive drugs, and cas

38 algorithms and counselling programmes; free antihypertensive and statin medications recommended by N

39 Medications, including antihypertensives and antidiabetics, along with dietary

40 the use of the structure of renin to design antihypertensives and the structure of HIV protease in d

41 eal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflammatory properties of ci

42 arminative, stimulant, antiseptic, diuretic, antihypertensive, and hepatoprotective activities.

43 ommonly used drugs, such as anti-infectives, antihypertensives, and cholesterol lowering agents.

44 pirical investigations, with 1 study each on antihypertensives, anti-infectives, central nervous syst

45 liferative, antiinflammatory, antimicrobial, antihypertensive, antihypercholesterolemic, neuroprotect

46 ng biological activity, including those with antihypertensive, antimicrobial, immunomodulatory, opioi

47 ha-amylase and alpha-glucosidase inhibition, antihypertensive, antioxidant and proteolytic activities

48 thocyanidin contents and the antioxidant and antihypertensive capacities were measured.

49 No single antihypertensive class was associated with prevention or

50 out pass rates, sensitivity varied from 30% (antihypertensive class) to 100% (coronary risk assessmen

51 ication was defined by the addition of a new antihypertensive class, and separately, titration by the

52 ification, antihypertensive intensification, antihypertensive class, carotid stenosis intervention, a

53 urther, we assessed the effects of different antihypertensive classes on ibrutinib-related HTN.

54 with antioxidant properties, we selected the antihypertensive CNS-penetrant medication indapamide for

55 s finding allows us to identify and validate antihypertensive combinations, offering a generic, power

56 timate [95% CI]: 22.5 [16.5-28.6], P<0.001), antihypertensives (DID estimate [95% CI]: 63.2 [47.3-79.

57 In adults with hypertension, how do various antihypertensive drug classes differ in their benefits a

58 Genetic proxies for the effect of antihypertensive drug classes were identified as variant

59 tigational drug was compared with the common antihypertensive drug nifedipine, which has 4.5-fold sel

60 lood pressure, adding meaningful efficacy to antihypertensive drug regimens.

61 encing data to identify molecular markers of antihypertensive drug response.

62 mm Hg, [-9.47 to -0.79]) as their additional antihypertensive drug than in those receiving a thiazide

63 ere grouped according to recommendations for antihypertensive drug therapy in the 2017 ACC/AHA guidel

64 with randomisation stratified by additional antihypertensive drug use and insulin use at baseline, i

65 We aimed at evaluating racial differences in antihypertensive drug utilization patterns and blood pre

66 was not being treated or was taking only one antihypertensive drug) to receive a daily regimen of 5 m

67 Spironolactone is an effective antihypertensive drug, especially for patients with resi

68 Here, we investigate how the FDA-approved antihypertensive drug, guanabenz, which has a favorable

69 with guanabenz acetate (GA), an FDA-approved antihypertensive drug, reduces the size and number of nu

70 scriptions and >= 180 defined daily doses of antihypertensive drugs (AHTs) within a year, during a me

71 VTDR, we also found novel associations with antihypertensive drugs (OR: 0.18; 95% CI: 0.06-0.61) and

72 management therefore often requires multiple antihypertensive drugs and concurrent treatment of dysli

73 Novel factors associated with VTDR include antihypertensive drugs and statins.

74 ssociation between use of ACEI/ARBs vs other antihypertensive drugs and the incidence rate of a COVID

75 Although antihypertensive drugs are widely available, in many pat

76 ent submitted to medical therapy was free of antihypertensive drugs at 12 months.

77 HTN trial, the prevalence of nonadherence to antihypertensive drugs at 6 months was high ( approximat

78 or uncontrolled intraocular pressure despite antihypertensive drugs combined to cyclophotocoagulation

79 have an influence: 41.7% of patients taking antihypertensive drugs experienced a severe reaction com

80 nce of baseline comorbidities, and trials of antihypertensive drugs for indications other than hypert

81 ore associated with heart failure than other antihypertensive drugs in patients.

82 iption of lipid-lowering, anticoagulant, and antihypertensive drugs is important to reduce the incide

83 eve recommended blood pressure levels on >=3 antihypertensive drugs of different classes.

84 Taking antihypertensive drugs seemed to have an influence: 41.7

85 f controls; ACEI/ARB use compared with other antihypertensive drugs was not significantly associated

86 ribed when lipid-lowering, anticoagulant, or antihypertensive drugs were clinically indicated but wer

87 igible for lipid-lowering, anticoagulant, or antihypertensive drugs were not prescribed them prior to

88 Lipid-lowering therapy, antihypertensive drugs, and anticalcific therapy have be

89 as the use of other antihypertensive and non-antihypertensive drugs, and case patients had a worse cl

90 hageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the

91 In the absence of new antihypertensive drugs, it is important that healthcare

92 al outcomes) based on blood pressure, use of antihypertensive drugs, plasma potassium and aldosterone

93 rugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hy

94 consisted of withdrawal of antidiabetes and antihypertensive drugs, total diet replacement (825-853

95 ion comprised withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (825-853

96 al side effects and repurposing potential of antihypertensive drugs, which are among the most commonl

97 ir products, and may guide the design of new antihypertensive drugs.

98 right after generic commercialization for 3 antihypertensive drugs.

99 s, and 25% (1,740/7,008) were not prescribed antihypertensive drugs.

100 icated, 3,194 anticoagulant drugs, and 7,008 antihypertensive drugs.

101 The antioxidant activity, antihypertensive effect and prebiotic activity of Mailla

102 system contribute, at least in part, to the antihypertensive effect of DHI in SHR.

103 In anti-DBH-SAP injected SHR, the antihypertensive effect of repeated LV injection of lira

104 In this study, we evaluated the antihypertensive effects and mechanism of action of Mb o

105 od pressure and the tissue that mediates its antihypertensive effects are currently unknown.

106 udy we aim to evaluate the mechanisms of the antihypertensive effects of Kefir in the two-kidney one-

107 gical research supporting the preventive and antihypertensive effects of major lifestyle intervention

108 a stabilized alphaAnalogue, by mediating (1) antihypertensive effects, (2) attenuating cardiac remode

109 a known antioxidant that is thought to have antihypertensive effects, the mechanism whereby pomegran

110 antidiabetic, antioxidative, antiobesity and antihypertensive effects.

111 n alone was sufficient to induce significant antihypertensive effects.

112 We used two of these antihypertensives (felodipine and nilvadipine) for admin

113 hydropyridines (DHP), the most commonly used antihypertensives, function by inhibiting the L-type vol

114 supports the potential use of spent hens as antihypertensive functional food ingredients and nutrace

115 inhibitory activity among other and in vivo antihypertensive, hypoglycemic or anti-inflammatory acti

116 sed controlled trial, we compared these oral antihypertensives in two public hospitals in Nagpur, Ind

117 However, antihypertensive initiation was associated with a lower

118 ion, cholesterol medication intensification, antihypertensive intensification, antihypertensive class

119 e clinical response to hydralazine, an acute antihypertensive, is dosing time-dependent and greatest

120 hanges in the use of and adherence to common antihypertensive, lipid-lowering, and hypoglycemic medic

121 ein ratio; diabetes; body mass index; use of antihypertensive, lipid-lowering, or anticholinergic med

122 e found that participants taking any type of antihypertensive medication (beta = -0.83; 95% confidenc

123 oxytyramine, by preventing interference from antihypertensive medication (beta-blockers).

124 BP >=80 mm Hg with the use of >=3 classes of antihypertensive medication (including a diuretic) or us

125 ith hypertension who are not recommended for antihypertensive medication according to the 2017 ACC/AH

126 ith hypertension who are not recommended for antihypertensive medication according to the 2017 ACC/AH

127 The presence of structural abnormalities or antihypertensive medication also correlated statisticall

128 ociation between initiating and intensifying antihypertensive medication and serious fall injuries in

129 s with prevalent CV disease and those taking antihypertensive medication at baseline.

130 of participants with diabetes were receiving antihypertensive medication at recruitment and 1% were r

131 Children on antihypertensive medication had impaired physical functi

132 njury was increased during the 15 days after antihypertensive medication initiation (odds ratio, 1.36

133 scular disease was a novel consideration for antihypertensive medication initiation in the 2017 Ameri

134 Antihypertensive medication initiation was defined by a

135 Antihypertensive medication nonadherence and the white c

136 Prevalent hypertension was defined as taking antihypertensive medication or having systolic blood pre

137 eneficiaries initiated, added a new class of antihypertensive medication or titrated therapy within 1

138 were randomized (1:1 ratio) to a strategy of antihypertensive medication reduction (removal of 1 drug

139 The findings suggest antihypertensive medication reduction in some older pati

140 This study aimed to establish whether antihypertensive medication reduction is possible withou

141 cluding a diuretic) or use of >=4 classes of antihypertensive medication regardless of BP level.

142 Patients on antihypertensive medication seem to be the most vulnerab

143 n uncontrolled blood pressure, and continued antihypertensive medication use (medication adherence ra

144 ssure of at least 90 mm Hg, or self-reported antihypertensive medication use in the previous 2 weeks.

145 ts with at least a 50% reduction in baseline antihypertensive medication use lasting at least 6 mo.

146 Antihypertensive medication use was self-reported.

147 olic blood pressure, current smoking status, antihypertensive medication use, diabetes mellitus, hist

148 ressure, fasting glucose, total cholesterol, antihypertensive medication use, glomerular filtration r

149 16%-37%) had a durable reduction in baseline antihypertensive medication use.

150 Analyses were stratified by antihypertensive medication use.

151 ased on average blood pressure >/=140/90 and antihypertensive medication use.

152 ies, body mass index, SBP, diastolic BP, and antihypertensive medication use.

153 A pharmacometabolomics study of antihypertensive medication was conducted and data were

154 (95% CI: 30.1% to 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (9

155 (95% CI: 30.1% to 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (9

156 ic ethnicity and requirement for more than 1 antihypertensive medication were independently associate

157 r hypertension not currently recommended for antihypertensive medication who are at high risk for CV

158 ge 1 or stage 2 hypertension recommended for antihypertensive medication with BP <160/100 mm Hg, thos

159 were used to investigate the association of antihypertensive medication with OCT measurements of RNF

160 Among participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg,

161 vated BP or hypertension not recommended for antihypertensive medication with versus without either e

162 Among U.S. adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.

163 Among US adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.

164 ed diagnosis of hypertension, current use of antihypertensive medication, and blood pressure of less

165 duration, smoking, systolic blood pressure, antihypertensive medication, and BMI.

166 d pressure (BP) thresholds for initiation of antihypertensive medication, and BP target goals.

167 he percentage of U.S. adults recommended for antihypertensive medication, and more intensive BP lower

168 the percentage of US adults recommended for antihypertensive medication, and more intensive BP lower

169 tension, implications of recommendations for antihypertensive medication, and prevalence of BP above

170 tension, implications of recommendations for antihypertensive medication, and prevalence of BP above

171 atment received an average of one additional antihypertensive medication, and the systolic blood pres

172 >=130 mm Hg or diastolic BP >80mm Hg, use of antihypertensive medication, or self-report of a diagnos

173 with hypertension despite taking at least 1 antihypertensive medication, paroxysmal atrial fibrillat

174 60.1-76.0) among those taking and not taking antihypertensive medication, respectively.

175 Among participants taking antihypertensive medication, the regression-derived thre

176 Among participants not taking antihypertensive medication, the regression-derived thre

177 ion, defined as BP >= 140/90 mm Hg or taking antihypertensive medication, were advised to visit a doc

178 to ensure patient compliance with absence of antihypertensive medication.

179 overt cardiovascular disease, and no use of antihypertensive medication.

180 intensive BP lowering for many adults taking antihypertensive medication.

181 intensive BP lowering for many adults taking antihypertensive medication.

182 133 mm Hg, respectively, among those taking antihypertensive medication.

183 ic BP level of 90 mm Hg or higher, or use of antihypertensive medication.

184 ambulatory visit received an order for a new antihypertensive medication.

185 BP >=80 mm Hg with use of 1 to 2 classes of antihypertensive medication; and resistant BP as systoli

186 c characteristics (age, sex, income); use of antihypertensive medication; smoking; tooth loss; dental

187 Lowering high blood pressure with specific antihypertensive medications (AHMs) could reduce the bur

188 nfidence interval: 2.15-17), and about their antihypertensive medications (odds ratio: 6.48; 95% conf

189 3362 sites, 8.1% (95% CI 7.2-9.1) stocked no antihypertensive medications and 33.8% (32.2-35.4) stock

190 Hg after a 4-week discontinuation of up to 2 antihypertensive medications and a suitable renal artery

191 tigation, as do associations between certain antihypertensive medications and death.

192 am group (p=0.008) and the average number of antihypertensive medications and defined daily dose were

193 oring was most effective in those with fewer antihypertensive medications and higher baseline sBP up

194 The effect of antihypertensive medications and lowering sodium intake

195 ility, cost, and prescription patterns of 62 antihypertensive medications at primary health-care site

196 130 to 180 mm Hg (depending on the number of antihypertensive medications being taken), and high card

197 maintained at 6 months with less prescribed antihypertensive medications compared with a sham contro

198 t current patterns of access to, and use of, antihypertensive medications in Chinese primary health c

199 on (RHT) although nonadherence to prescribed antihypertensive medications is common in patients with

200 Deprescribing of antihypertensive medications is recommended for some old

201 , 84.8 years; 276 [48.5%] women; median of 2 antihypertensive medications prescribed at baseline), 53

202 scular deficits in AD.SIGNIFICANCE STATEMENT Antihypertensive medications that target the renin angio

203 Patients were to remain off antihypertensive medications throughout the first 2 mont

204 Increasing coverage of antihypertensive medications to 70% alone would delay 39

205 imely initiation and subsequent titration of antihypertensive medications to achieve individualised B

206 In a separate analysis, the use of antihypertensive medications was independently associate

207 Use of a greater number of antihypertensive medications was significantly associate

208 registration LVEF less than 65%, and use of antihypertensive medications were associated with an inc

209 han 150 mm Hg, and were receiving at least 2 antihypertensive medications were included.

210 at least a 30% reduction in total number of antihypertensive medications while maintaining BP less t

211 Reduction of >/=30% of the total number of antihypertensive medications while maintaining controlle

212 s reduction of >/=30% of the total number of antihypertensive medications while maintaining systolic

213 blood pressure >/=90 mm Hg, or initiation of antihypertensive medications).

214 Among older patients treated with multiple antihypertensive medications, a strategy of medication r

215 Use of 2 or more antihypertensive medications, ACEI, and diuretics were a

216 is, 30.1% (30.0-30.2) were taking prescribed antihypertensive medications, and 7.2% (7.1-7.2) had ach

217 nd regional estimates of current coverage of antihypertensive medications, and cause-specific mortali

218 3 levels were more likely White race, taking antihypertensive medications, and had lower kidney funct

219 the effect of differential cotreatment with antihypertensive medications, and long lag time to clini

220 Owing to the widespread use of antihypertensive medications, global mean blood pressure

221 Key secondary outcomes were number of antihypertensive medications, hypertension remission, an

222 will need to improve access to, and use of, antihypertensive medications, paying particular attentio

223 s, underlying medical conditions, outpatient antihypertensive medications, recorded symptoms, vital s

224 h pre- or stage 1 hypertension and not using antihypertensive medications, were randomized to either

225 to explore the efficacy and side effects of antihypertensive medications.

226 am procedure among patients not treated with antihypertensive medications.

227 ients exhibited poor adherence to prescribed antihypertensive medications.

228 tients were drug-naive or discontinued their antihypertensive medications.

229 ervation on blood pressure in the absence of antihypertensive medications.

230 the availability, cost, and prescription of antihypertensive medications.

231 s and 85 patients (75.9%) were taking ocular antihypertensive medications.

232 icacy of renal denervation in the absence of antihypertensive medications.

233 e in association with five common classes of antihypertensive medications.

234 afely lower blood pressure in the absence of antihypertensive medications.

235 e hypertension in the presence or absence of antihypertensive medications.

236 success was defined as IOP <=21 mmHg without antihypertensive medications.

237 microbiome modulates response to statins and antihypertensive medications.

238 per 1000 Medicaid beneficiaries of statins, antihypertensives, P2Y12 inhibitors, and direct oral ant

239 duct, as the starting material for preparing antihypertensive peptides.

240 nce it is a good source of antioxidative and antihypertensive peptides.

241 d by an O:W emulsion on the integrity of the antihypertensive peptides.

242 ly hypertensive rat model to investigate the antihypertensive properties of pomegranate extract.

243 All oral antihypertensives reduced blood pressure to the referenc

244 olactone or amiloride to the standard 3-drug antihypertensive regimen is effective at getting the blo

245 to TD from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) (50 whites) and from P

246 (EA) from the Pharmacogenomic Evaluation of Antihypertensive Responses-2 (PEAR-2) study and replicat

247 g combination treatment as first step of the antihypertensive therapeutic intervention.

248 ular behaviors can provide insight to inform antihypertensive therapeutics in individuals with varian

249 These neurons may be a promising target for antihypertensive therapeutics.

250 ith statins and other lipid-lowering agents, antihypertensive therapies, and antihyperglycemic treatm

251 versus <=145 mm Hg (standard treatment) with antihypertensive therapies.

252 rovide a potential target for individualized antihypertensive therapies.

253 ing fixed-combination, low-dose, triple-pill antihypertensive therapy (consisting of amlodipine, telm

254 However, participants receiving antihypertensive therapy (with blood pressure controlled

255 is the optimal target for BP lowering during antihypertensive therapy in adults?

256 aptured year-by-year adherence to statin and antihypertensive therapy in both study groups and estima

257 hypotension; the effectiveness of nocturnal antihypertensive therapy in patients with coexistent neu

258 ant clinical implications since titration of antihypertensive therapy is currently based on SBP.

259 59) for those nonadherent both to statin and antihypertensive therapy, 1.82 (95% CI: 1.43 to 2.33) fo

260 those non-adherent to statin but adherent to antihypertensive therapy, and 1.30 (95% CI: 0.53 to 3.20

261 terol, estimated glomerular filtration rate, antihypertensive therapy, diabetes mellitus, and smoking

262 hough black patients received more intensive antihypertensive therapy, Hispanics were undertreated.

263 sis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration, and reduc

264 relative to those who adhered to statins and antihypertensive therapy, the odds ratio at the year of

265 ther help advance personalized approaches to antihypertensive therapy.

266 number needed to treat for both statins and antihypertensive therapy.

267 ssociated with nonadherence to statin and/or antihypertensive therapy.

268 determinant for hypertension and response to antihypertensive therapy.

269 %-0.6%) also met the guideline threshold for antihypertensive therapy.

270 those adherent to statin, but nonadherent to antihypertensive, therapy.

271 edictor for LVH among patients not receiving antihypertensive treatment (P = 0.025).

272 n of a recommended standardized stepped-care antihypertensive treatment (SSAHT) to the randomized end

273 lood pressure than standardized stepped-care antihypertensive treatment alone.

274 care antihypertensive treatment, or the same antihypertensive treatment alone.

275 levels, and the use of CVD risk for guiding antihypertensive treatment among subgroups including old

276 nd common challenges that will likely impact antihypertensive treatment and clinical outcomes in pati

277 in addition to blood pressure (BP) to guide antihypertensive treatment is an active area of research

278 olute CVD risk reduction that can occur when antihypertensive treatment is guided by CVD risk.

279 rospective observational study nested in the Antihypertensive Treatment of Acute Cerebral Hemorrhage

280 Haemorrhage Trial (INTERACT2) and the second Antihypertensive Treatment of Acute Cerebral Hemorrhage

281 We report the influence of adherence to antihypertensive treatment on blood pressure control.

282 review potential challenges in implementing antihypertensive treatment recommendations that incorpor

283 l denervation plus standardized stepped-care antihypertensive treatment resulted in a greater decreas

284 the present review, we propose to adapt the antihypertensive treatment using an easy-to-apply visual

285 y nonadherent patients (7/40 versus 4/45) to antihypertensive treatment were not different in the ren

286 screened, are aware of their diagnosis, take antihypertensive treatment, and have achieved control an

287 terol level, systolic blood pressure, use of antihypertensive treatment, current cigarette smoking, d

288 , diastolic blood pressure, current smoking, antihypertensive treatment, diabetes mellitus, prevalent

289 l denervation plus standardized stepped-care antihypertensive treatment, or the same antihypertensive

290 ing CVD risk in conjunction with BP to guide antihypertensive treatment, the broad distribution in CV

291 ing CVD risk in combination with BP to guide antihypertensive treatment.

292 son with participants who were not receiving antihypertensive treatment.

293 mendations to discontinue guideline-directed antihypertensive treatment.

294 nd those who are normotensive, additively to antihypertensive treatments.

295 findings could facilitate the search for new antihypertensive treatments.

296 idence interval [CI], 1.66-4.41; P < 0.001), antihypertensive use (OR, 2.03; 95% CI, 1.20-3.46; P = 0

297 SD 12), 15 patients (50%) were men, and mean antihypertensive use was 4.4 drugs (1.4).

298 iral load, CD4 lymphocyte count, statin use, antihypertensive use, and antiretroviral medication use

299 , labile international normalized ratio, and antihypertensive use.

300 Group 1 patients who were on antihypertensives were washed out for a 4-week period, p